Cannabis Law Report

NOVEMBER 3, 2021

. – A Los Angeles man pleaded guilty today to being the head of a conspiracy involving the distribution of wholesale quantities of synthetic cannabinoids—commonly known as “spice” or “K2”—and laundering millions of dollars in the proceeds of the sale of that spice. Adame, Inspector in Charge of the Washington Division of the U.S. 1:20-cr-76.

Cannabinoids 98

Cannabinoids Packaging DEA Law 98

Cannabis Law Report

NOVEMBER 11, 2021

Cannabinoid Hemp Program Regulations (Finally) Finalized. While much attention is focused on New York’s adult-use cannabis market, the CCB and Office of Cannabis Management (OCM) are also responsible for overseeing both the Medical Marijuana and Cannabinoid Hemp Programs. cannabinoid hemp and hemp extract.”

Programs 52

Programs Hemp Supply Chain Seed-To-Sale 52

Canna Law Blog

FEBRUARY 2, 2020

The Commission is also concerned about “inevitable delays in laboratory results because of high sample volumes” which are exacerbated by the interim hemp rules’ requirement that labs testing hemp to obtain DEA registration. For now, we just have guidance documents. According to a February 8, 2019, NCDA press release.

Hemp 103

Hemp CBD Agriculture Cultivation 103

Cannabis Law Report

NOVEMBER 2, 2021

Delta-8 THC is making big waves in the cannabis industry at the minute, but with warnings from the FDA and CDC , not to mention harrowing accounts from users , it’s clear there’s more going on with the novel cannabinoid than meets the eye. Those cannabinoids are easier to extract so there’s less risk with doing it wrong.

THC 96

THC CBD Legalization Vaping 96

CannaMD

SEPTEMBER 15, 2020

Regular cannabis is not subject to cannabinoid limits and/or ratios. Any other documentation that provides proof of residential address as determined by department rule. A progress note or physician-signed acknowledgment is ideal documentation (as long as it includes your doctor’s name, signature, and your diagnosed condition).

Law 126

Law Marijuana Patients Treatment 126

Cannabis Law Report

JULY 12, 2019

International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

NORML

SEPTEMBER 20, 2019

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. It’s been nearly three years since the DEA announced its revolutionary cultivator program. Dr. Sue Sisley. Later that night, everyone celebrated at a hotel bar.

DEA 231

DEA Research and Development Clinical Trials Patients 231